Biotech Values

[turtlepower]

ALTH - More reasonable numbers from Adam

Allos' pralatrexate addresses a small population of about 5,000 patients with peripheral T-cell lymphoma (PTCL) in the U.S., but the drug would be the first approved to treat the disease. Today, PTCL patients are generally treated with a hodgepodge of chemotherapy regimens, none of which work very well.

I'd put pralatrexate peak sales in the U.S. between $200 million and $400 million (assuming premium pricing), with upside coming from expanded use in other cancers, including lung, if such use is justified by clinical data.

http://www.thestreet.com/story/10504525/4/biotech-stock-mailbag-gilead-still-got-it.html